key: cord-1043933-9rcqqkid
authors: Maier, Cheryl; Wong, Andrew; Woodhouse, Isaac; Schneider, Frank; Kulpa, Deanna; Silvestri, Guido
title: Broad Auto-Reactive IgM Responses Are Common In Critically Ill COVID-19 Patients.
date: 2020-12-31
journal: Res Sq
DOI: 10.21203/rs.3.rs-128348/v1
sha: 82e19f7aa4ac7e6b7dac3b4ef264766e819ae26e
doc_id: 1043933
cord_uid: 9rcqqkid

The pathogenesis of severe COVID-19 remains poorly understood. While several studies suggest that immune dysregulation plays a central role, the key mediators of this process are yet to be defined. Here, we demonstrate that plasma from a high proportion (77%) of critically ill COVID-19 patients, but not healthy controls, contains broadly auto-reactive immunoglobulin M (IgM), and only infrequently auto-reactive IgG or IgA. Importantly, these auto-IgM preferentially recognize primary human lung cells in vitro, including pulmonary endothelial and epithelial cells. By using a combination of flow cytometry, LDH-release assays, and analytical proteome microarray technology, we identified high-affinity, complement-fixing, auto-reactive IgM directed against 263 candidate auto-antigens, including numerous molecules preferentially expressed on cellular membranes in pulmonary, vascular, gastrointestinal, and renal tissues. These findings suggest that broad IgM-mediated autoimmune reactivity may be involved in the pathogenesis of severe COVID-19, thereby identifying a potential target for novel therapeutic interventions.

preferentially expressed on cellular membranes in pulmonary, vascular, gastrointestinal, and renal tissues. These ndings suggest that broad IgM-mediated autoimmune reactivity may be involved in the pathogenesis of severe COVID-19, thereby identifying a potential target for novel therapeutic interventions.

Although SARS-CoV-2, the etiological agent for COVID-19, is initially and preferentially tropic for respiratory cellular targets [3] [4] [5] , its pathogenetic effects can be systemic. Indeed, dysregulated coagulopathy and systemic in ammation are hallmark characteristics of severe COVID-19 6, 7 , which involves acute respiratory distress syndrome (ARDS) as well as alterations of other organs 8, 9 . The pathogenic mechanisms responsible for the most severe clinical progression of COVID-19 are yet poorly understood, although they appear to be multifactorial in nature. In this context, a relatively underexplored mechanistic pathway relates to autoimmunity. Autoantibodies that neutralize type-1 interferons have been described in severe adult COVID-19 10 , as have autoantibodies against self-antigens associated with systemic lupus erythematosus and Sjogren's disease in severe pediatric COVID-19 11 . Additional reports of antiphospholipid autoantibodies have been associated with thrombotic events 12, 13 thereby linking immune dysregulation with thrombosis in severe COVID-19 14 . These observations underscore the urgent need to closely examine the intersection of immunopathology and severe COVID-19, particularly in pulmonary and vascular sites.

In this study, we rst sought to detect auto-reactive antibodies in patient plasma using a comprehensive screening approach incorporating diverse and relevant cell types. Plasma samples were obtained from 64 patients hospitalized for COVID-19, including 55 patients with critical illness admitted to the intensive care unit (ICU; COVID ICU) and 9 patients with less severe disease admitted to the regular hospital oor (COVID non-ICU). Plasma was also obtained from 13 critically ill patients without SARS-CoV-2 infection (non-COVID ICU), 9 outpatients with hypergammaglobulinemia (Hyper-γ), and 12 healthy donors (Supplementary Table 1 ). Samples were screened for the presence of IgA, IgG, and IgM antibodies against 5 human cell types comprising of primary epithelial or endothelial cells of pulmonary, gut, or renal origin, as well as a highly utilized immortalized cell line with a pulmonary endothelial phenotype. Given that these cells have never been exposed to SARS-CoV-2 naïve, antibodies detected in this assay re ect the targeting of self-antigens and are not the consequence of reactivity against SARS-CoV-2 antigens.

Analysis of cells using conventional ( Figure 1a ) and imaging ow cytometry (Figure 1b-d) revealed the presence of antibodies binding to the plasma membrane. Scored against healthy and non-COVID controls, auto-reactive IgA, auto-reactive IgG and auto-reactive IgM were detected in 28 (51%), 23 (42%), and 51 (93%) out of 55 COVID ICU patients, respectively (Figure 1e ). In each reaction, the percentage of cells that stained positively for IgM antibodies was far greater than IgA or IgG, suggesting higher circulating auto-reactive IgM titers. Although COVID ICU patients were associated with higher circulating interleukin-6 (IL-6) and C-reactive protein (CRP) (Supplementary Figure 1a-b) , only auto-IgM levels were modestly associated with increased plasma interleukin-6 (IL-6) ( =0.29, p=0.0056; Supplementary Figure   2a -b). Of note, most COVID ICU patient plasma showed IgA, IgG, IgM, or a combination of, reactivity with cells of pulmonary origin (Figure 1f ). Although a signi cant percentage of COVID ICU patients had detectable levels of auto-reactive IgA and IgG, we focused on auto-reactive IgM given its substantially higher titers and frequency. Overall, this rst set of data revealed that high-titer auto-reactive IgM are frequently detected in patients with severe COVID-19 and that the reactivity is most pronounced against cells of pulmonary epithelial and endothelial origin.

We next sought to understand which auto-antigens are targeted by these circulating auto-reactive IgM in COVID-19 patients. Plasma samples from COVID ICU patients with strong auto-reactive IgM titers (n=5), non-COVID ICU patients (n=3) and healthy controls (n=4) were surveyed in analytical human proteome microarrays (HuProt v4 array). The array epxresses over 21,000 intact proteins, therefore allowing for a thorough and comprehensive investigation of potential binding targets for auto-reactive IgM antibodies.

For stringency, a potential binding target was considered for any protein that had a uorescence signal at least 4 standard deviations (Z-score>4) above the array mean. Additionally, the target had to possess a uorescence signal at least 2 Z-scores above the same target across all healthy controls. This strict approach resulted in the identi cation of 260 candidate autoantigens that were uniquely linked to COVID ICU patients (Figure 2a and Supplementary Table 2 ). Of note, the auto-reactive IgM repertoire in COVID ICU patients is broad, and the candidate targets infrequently overlapped among different patients included in this cohort ( Figure 2b ). It is very likely, and anticipated, that interrogation of additional plasma samples from patients with severe COVID-19 by proteome microarray would identify further auto-antigen targets, and that the individual antigenic targets are likely less relevant to the disease pathogenesis than the overall abundance, breadth, and tissue speci city of the observed auto-antibodies.

Given the high Z-scores of each candidate target, the auto-reactive IgM antibodies are circulating at robust titers and/or bind with high avidity to the respective targets. We next sought to determine whether the candidate autoantigens were expressed in key tissue types. Using arterial tissues as surrogates for endothelial sites, small intestinal and colonic tissues as surrogates for gastrointestinal sites, as well as renal, neural, and pulmonary sites, we found 226 candidate autoantigens expressed at above-background levels in these cell types ( Figure 2c ). Importantly, we identi ed 16 autoantigens associated with the human plasma membrane proteome 15 and therefore considered these molecules as important prospective candidate targets for circulating pathogenic auto-reactive IgM (Figure 2d ). We next investigated whether these proteins shared similar motifs. Although N-linked glycosylation was predicted in 11 candidate autoantigens, heterogeneity in amino acid sequences anking predicted N-linked glycosylated residues indicated minimal in uence of N-linked glycosylation on potential IgM binding motifs (Supplementary Figure 3a) . However, an arti cial neural network prediction model 16 Complement-dependent cytotoxicity (CDC) and complement deregulation have been proposed to play a roles in the pathogenesis of ARDS 26 . Additionally, as there is considerable pulmonary microangiopathy observed in severe COVID-19 patients 27, 28 , it is conceivable that CDC can precede or even cause the damage to the pulmonary endothelium. Given the observed IgM and C4d binding to pulmonary targets and to con rm that the auto-reactive IgM can mediate CDC, we next tested plasma samples from severe COVID-19 patients for their capability of xing complement and inducing cytotoxicity in vitro. To this end, we investigated patient plasma samples that showed greater than 10% binding to the respective cell type in the screening assay. Interestingly, we consistently observed higher rates of CDC in cells of pulmonary origin (Figure 3d-h) . In addition, while non-COVID-19 ICU patient plasma samples induced limited or no cell death, most COVID-19 ICU patients plasma samples induced cell death at frequencies proportional to their measured level of cell binding (Figure 3i ). Collectively, these data indicate that auto-reactive IgM present in plasma from severe COVID-19 patients can x complement and induce cytotoxicity.

The identi cation of auto-reactive IgM as a potential contributing factor to the pathogenesis of severe COVID-19 has two immediate implications. First, this observation may explain how COVID-19 is disproportionately more serious in the elderly 29 , who typically manifest higher plasma levels of circulating auto-reactive antibodies 30 . This phenomenon would be exacerbated by decreases in functional T follicular helper cells that promote antibody class switching 31 , a process associated with better disease outcomes 32 . Given that IgM levels peak within a week of the clinical onset of COVID-19

and persist at similar levels for weeks thereafter 34 , the elderly face a protracted period where there is steadfast secretion of auto-reactive IgM that maintain relatively low a nity for the same epitope without either switching to alternate antibody class types or undergoing somatic hypermutation and a nity maturation. In this perspective, the elderly may be more prone to severe COVID-19 due to a more protracted exposure to the cytopathic effects of auto-reactive IgM.

Secondly, it is conceivable that this type of immunopathology can be limited by therapeutic interventions that inhibit the IgM-complement axis. In the immediate term, this approach could mitigate the SARS-CoV-2 associated alveolar damage and ARDS [35] [36] [37] , and consequently protect against mortality 38 and/or reduce the need for invasive mechanical ventilation 39 . In the long term, preservation of lung integrity may prevent pathogenic sequelae such as pulmonary brosis 40, 41 , which diminishes lung function postrecovery 42 . These therapeutic goals could be implemented through the use of immunosuppressants, such as dexamethasone, that can attenuate the production of auto-reactive IgM 43 , plasma exchange to remove auto-reactive IgM once formed 44 , or to synergize and supplement proposed anti-brotic therapies 45 . Alternatively, the complement cascade can be directly inhibited through conestat alfa 46 or eculizumab 46 , and indeed, both drugs are presently undergoing evaluation through clinical trials to determine e cacy 47 . Optimistically, our ndings cast support for interventions that can be readily and swiftly implemented in the clinic to alleviate or prevent serious COVID-19 complications.

In summary, we found that broadly auto-reactive IgM are common in the plasma of patients with severe COVID-19. These auto-reactive antibodies bind pulmonary epithelial and endothelial targets, at which point they can be potent mediators of cytopathicity through the recruitment of complement. Future studies will investigate the relationship between SARS-CoV-2 infection and the emergence of autoreactive antibodies, and determine whether immunosuppressive therapy can reduce the levels of autoreactive IgM in plasma and consequently attenuate the clinical severity of COVID-19.

Plasma Samples. Plasma samples were obtained from discarded clinical specimens at Emory University Hospital or from healthy donors in accordance with protocols approved by Emory's Institutional Review

Board. Patient demographics and characteristics were obtained by electronic chart review as summarized in Supplemental Table 1 .

Cells. HULEC-5a cells were obtained from the American Type Culture Collection (ATCC) and maintained in MCDB131 Medium (Gibco, Thermo Fisher) supplemented with 10ng/ml epidermal growth factor (Thermo and maintained in ENDO-Growth Medium (cat. no. EGK001, Neuromics). All cells were kept at 37ºC in a humidi ed incubator supplemented with 5% CO 2 and maintained between 50-80% con uence. Primary cells were grown in cell culture asks coated with gelatin (cat. no. 6950, CellBiologics) and used between 3-7 passages.

Flow cytometry detection of auto-antibodies. Plasma aliquots were stored at -80ºC and then thawed at 4ºC for use in assays. Cells were detached from culture asks using TrypLE Express reagent (Thermo Fisher) and resuspended in DPBS at a concentration of 5x10 5 cells/ml. 100µl of each cell suspension was added to 96-well U-bottom plates, and 50µl of patient or healthy donor plasma added and gently

mixed. An IgG positive control was performed by adding human anti-CD98 IgG (cat. no. Ab00361-10.0, Absolute Antibody, 2µl) to one well. Plates were transferred to 4ºC for one hour, after which cells were washed with cold DPBS and then incubated with an antibody cocktail containing a viability dye IL-6 ELISA. Plasma levels of IL-6 were quanti ed using a Human IL-6 ELISA kit (ab178013, Abcam) and following the manufacturer's instructions.

Histology. Five-micrometer sections from formalin-xed, para n-embedded lung tissue sections were tested for IgM expression using a rabbit anti-IgM polyclonal antibody (cat. no. F0203, Agilent, Santa Clara, CA) at 1:400 dilution and for C4d expression using a rabbit anti-C4d polyclonal antibody (cat. no.

04-BI-RC4D, ALPCO Diagnostics, Salem, NH) at 1:100 dilution. IgM staining was performed on a Dako Link48 Autostainer with the EnVision FLEX dual-link system (Dako, Carpinteria, California) after heatinduced epitope retrieval in citrate buffer for 30 minutes. C4d staining was performed on a Leica Bond III automated stainer with the Bond Polymer Re ne Detection Kit (Leica Microsystems, Bannockburn, IL) after on-board epitope retrieval using Bond epitope retrieval solution 1 (ER1) for 20 minutes. Images were analyzed in ImageJ using the IHC Image Analysis Toolbox for the enumeration of nuclei, and to identify stained regions. The Color Pixel Counter plugin was further used to quantify the extent of staining in each image.

Complement Fixing Assay. Target cells were dissociated from culture asks by TrypLE Express reagent (Gibco) and resuspended in PBS at a concentration of 1x10 6 cells/ml. 50µl of the cell suspension was transferred to wells of a 96-well V-bottom plate. 50µl of plasma was added to each well and plates were incubated at 4ºC for one hour. 2 non-COVID (ICU) and 2 healthy donor plasma samples without IgM reactivity were selected as controls. Cells were washed with cold DPBS twice and resuspended in 100µl

DPBS. 11µl of reconstituted rabbit complement (Low-Tox-M rabbit complement, Cedarlane) was added to each well. To one well, 0.1% Triton X-100 was added to induce cell lysis. Plates were then transferred to a 37ºC incubator for two hours. Plates were then centrifuged at 500g for 5 minutes to pellet cells. 50µl of the supernatant was transferred to a at-bottom 96-well plate in duplicate. 50µl of reconstituted lactose dehydrogenase assay reagent (CyQUANT LDH Cytotoxicity Assay, Invitrogen) was then added to each well, and the plate was subsequently protected from light and left at ambient temperature for 30 minutes, after which 50µl of the included stop solution was added. Absorbance was read at 490nm and 680nm (Varioskan LUX multimode plate reader, Thermo Fisher). Absorbance values at 680nm were subtracted from absorbances at 490nm and duplicate values averaged. Percentage cytotoxicity was calculated by comparing the absorbance values against the lysed-cell and healthy-donor controls.

Protein Array. 5 COVID-19 (ICU) and 3 non-COVID-19 (ICU) samples characterized as enriched with auto-IgM by the ow cytometry assay described above were submitted alongside 4 randomly chosen healthy control samples to CDI laboratories (Baltimore, MD) for antigen-speci city screening across >21,000 fulllength recombinant human protein targets (HuProt v4.0 proteome microarray).

Gene Expression Analysis. Tissue-level transcription pro les were based on the Transcript TPMs dataset provided by the GTEx Portal. Subcellular localization data provided by the Human Protein Atlas 15 guided the identi cation of plasma membrane proteins. For all analyses, plasma membrane proteins were those de ned as 'Enhanced' or 'Supported' for plasma membrane localization. Visualizations and heatmaps were generated with GraphPad Prism (v9.0) and RStudio Desktop (1.3.959). Predictions of N-and Olinked glycosylated sites were respectively provided by NetNGlyc 48 and YinOYang servers 16 , and only high-cutoff sites were chosen for further analysis. Amino acid probability graphs were generated with WebLogo 3. 

The innate immune system: ghting on the front lines or fanning the ames of COVID-19?

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

Multiorgan and Renal Tropism of SARS-CoV-2

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States

Immune Response, In ammation, and the Clinical Spectrum of COVID-19

COVID-19-associated coagulopathy: An exploration of mechanisms

Severe Covid-19

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Mapping Systemic In ammation and Antibody Responses in Multisystem In ammatory Syndrome in Children (MIS-C)

Antiphospholipid Antibodies in Critically Ill Patients With COVID-19

Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19

Pulmonary Angiopathy in Severe COVID-19: Physiologic, Imaging, and Hematologic Observations

Tissue-based map of the human proteome

Prediction of glycosylation across the human proteome and the correlation to protein function

Spontaneous Production of Immunoglobulin M in Human Epithelial Cancer Cells

Radiation-induced tumor immunity in patients with non-small cell lung cancer

Histopathology and ultrastructural ndings of fatal COVID-19 infections in Washington State: a case series

COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City

New insights into the mechanisms of pulmonary edema in acute lung injury

Baricitinib treatment resolves lower airway macrophage in ammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques

Pulmonary brosis: pathogenesis, etiology and regulation

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia

Complement as a target in COVID-19?

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Did we turn a blind eye? The answer is simply there. Peripheral pulmonary vascular thrombosis in COVID-19 patients explains sudden worsening of clinical conditions

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Cell Dysfunction Associated With Aging and Autoimmune Diseases

How T follicular helper cells and the germinal centre response change with age

Compromised humoral functional evolution tracks with SARS-CoV-2 mortality

Impact of Age on Hypermutation of Immunoglobulin Variable Genes in Humans

Serum IgA, IgM, and IgG responses in COVID-19

Acute Respiratory Distress Syndrome and Diffuse Alveolar Damage

ARDS and Diffuse Alveolar Damage: A Pathologist's Perspective

Acute respiratory distress syndrome

Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey

Timing of Intubation and Mortality Among Critically Ill Coronavirus Disease 2019 Patients: A Single-Center Cohort Study

Long term respiratory complications of covid-19

Pulmonary brosis secondary to COVID-19: a call to arms?

COVID-19 and risk of pulmonary brosis: the importance of planning ahead

Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial

COVID-19-associated hyperviscosity: a link between in ammation and thrombophilia?

Pulmonary brosis and COVID-19: the potential role for anti brotic therapy

Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement

Complement and protection from tissue injury in COVID-19

Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology

Nuclei are pseudocolored green. Distance bar indicates 10µm. IgM-stained plasma membrane indicated by white arrowheads. Representative images shown. e: The maximum observed auto-Ig staining percentage across all cell types, from each patient, are shown. f: Detected auto-Ig levels in speci c cell types are shown, per patient. For e and f, The 'ICU' label designates non-COVID ICU patients